EP300 and cancer: In addition, the p300 inhibitor C646 increased survival in a mouse model of leukemia.18 An impaired acetylation equilibrium is also observed in several solid tumors14, 19 including prostate,20, 21 colon22 and breast23 cancers with evidences for both HATs and deacetylases as potential drug targets.